Aptar Pharma has transferred manufacturing equipment for its Child-Resistant and Senior-Friendly Classic Nasal Pump from a plant in Germany to its facility in Congers, NY, the company said. According to Aptar, its child-resistant pump is used for every major brand of topical nasal decongestant spray marketed in the US.
The child-resistant pump was developed in response to a 2012 rule issued by the US Consumer Product Safety Commission (CPSC) requiring child-resistant packaging for any product containing at least 0.08 mg of imidazoline, a common ingredient in decongestant nasal sprays.
Aptar Pharma North America President Alex Theodorakis commented, “We are pleased to welcome the arrival of Aptar Pharma’s child-resistant assembly machine to our recently-expanded Congers, NY manufacturing site. This added manufacturing capacity enables us to offer the production of this key child-resistant/ senior-friendly feature to our customers domestically. Being closer to our customers continues to be of strategic importance to Aptar Pharma, and this new initiative enables us to continue to support our important North American marketplace and increase our demand reactivity.”
